Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble FcγRIIB significantly delayed onset of proteinuria, reduced histopathological findings and improved survival[57]. The gene discussed is FCGR2B; the disease is systemic lupus erythematosus.